Medicenna’s MDNA11 a promising alternative to checkpoint inhibitors
Medicenna's IL-2 super-agonist, MDNA11, successfully induced antitumour cells in animal…
Medicenna's IL-2 super-agonist, MDNA11, successfully induced antitumour cells in animal models, a pre-clinical study has revealed.